We believe that a future prospective study with more patients will improve these limitations by multivariable analyses and provide more reliable and dynamic information on the clinical utility of PR3-ANCA positivity in patients who are newly diagnosed with MPA. This evidence concerns the gene PRTN3 and microscopic polyangiitis.